Search results for " VACCINES"

showing 10 items of 472 documents

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination li…

2022

Patients with liver diseases, especially those with cirrhosis, have an increased mortality risk when infected by SARS-CoV-2 and therefore anti-SARS-CoV-2 vaccine has been recommended by leading Scientific Associations for all patients with chronic liver diseases. However, previous reports have shown a reduced antibody response following the full course of vaccination in immunosuppressed patients, including liver transplant recipients and several rheumatic diseases. This document, drafted by an expert panel of hepatologists appointed by the Italian Association for the Study of the Liver (AISF), aims to present the updated scientific data on the safety and efficacy of anti-SARS-CoV-2 mRNA vac…

Hepatitis AutoimmuneSettore MED/12 - GastroenterologiaCOVID-19 VaccinesHepatologySARS-CoV-2Liver DiseasesVaccinationGastroenterologyCOVID-19HumansSARS-CoV-2 mRNA vaccines autoimmune hepatitis immunosoppressionDigestive and Liver Disease
researchProduct

Spontaneous Remission of Recalcitrant Warts in Girls After Human Papillomavirus Vaccination

2016

Histologybusiness.industrySpontaneous remissionDermatologyVirologyHuman papillomavirus vaccinationPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciencesRemission inductionPapillomavirus Vaccines0302 clinical medicine030220 oncology & carcinogenesisImmunologyMedicinebusinessActas Dermo-Sifiliográficas (English Edition)
researchProduct

Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations

2021

AbstractHuman papilloma virus infection (HPV) is the most common sexually transmitted disease. Little is known about male infection. Nonavalent vaccine against types 6/11/16/18/31/33/45/52/58 was approved and neutral gender immunization programs have been proposed. This study evaluates the potential impact of nonavalent vaccine compared to quadrivalent in male living in Sicily (Italy). 58.7% of samples were HPV positive and forty-four types of HPV were identified. A significant higher estimated coverage of nonavalent vaccine than quadrivalent was observed (64.3% vs. 45.8%), with absolute and relative additional impact of 20.1% and 47.2%, respectively. Low impact of the vaccine were calculat…

Hpv genotypesSexually transmitted diseaseAdultMalemedicine.medical_specialtyScienceDiseasesMicrobiologyArticle03 medical and health sciencesYoung Adult0302 clinical medicineMedical researchHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Internal medicineMedicineHumansHuman papilloma virus infection030212 general & internal medicinePapillomavirus VaccinesPapillomaviridaeSicilyAgedPotential impactMultidisciplinarybusiness.industryHPV PositivePapillomavirus InfectionsQHealth careRMiddle Aged030220 oncology & carcinogenesisCase-Control StudiesMedicinebusinessSexual contactHPV nonavalent vaccine men infectious desease
researchProduct

Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addi…

2010

Control of human cytomegalovirus (HCMV) infection correlates with the reconstitution of antiviral T lymphocytes in haematopoietic stem cell transplant recipients. A vaccine to foster this reconstitution and to ameliorate the severe consequences of HCMV reactivation is yet unavailable. This work focused on providing a rationale for the amendment of the yields and the antigenic composition of a vaccine, based on subviral dense bodies (DB) of HCMV. Modified DB were generated that contained the HLA-A2 presented IE1 model peptide TMYGGISLL, integrated at different positions in the major DB protein pp65. Insertion at position W175 of pp65 allowed efficient formation of recDB in the cytoplasm of i…

Human cytomegalovirusCD4-Positive T-Lymphocytesvirusesmedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusMice TransgenicBiologyCD8-Positive T-LymphocytesAntibodies ViralVirusCell LineViral Matrix ProteinsCytomegalovirus VaccinesMiceAntigenmedicineCytotoxic T cellAnimalsHumansNeutralizing antibodyAntigens ViralMice Inbred BALB CGeneral VeterinaryGeneral Immunology and MicrobiologyPublic Health Environmental and Occupational Healthvirus diseasesmedicine.diseasePhosphoproteinsVirologyAntibodies NeutralizingMutagenesis InsertionalInfectious DiseasesCytomegalovirus InfectionsDNA Viralbiology.proteinMolecular MedicineAdjuvantCD8Vaccine
researchProduct

Cytomegalovirus and varicella–zoster virus vaccines in hematopoietic stem cell transplantation

2009

Impairment of cellular immunity upon hematopoietic stem cell transplantation (HSCT) may lead to serious clinical manifestations induced by human cytomegalovirus (HCMV) and varicella-zoster virus (VZV) infections. Although the clinical presentations, preferential organ involvement and clinical courses are different, infections with both herpesviruses are similar with respect to many pathophysiological aspects and the therapeutic strategies that are employed to combat them. Antiviral drug prophylaxis and therapy are successfully used to limit the risk of reactivated HCMV and VZV infections, but are unable to absolutely prevent episodes of virus disease in long-term follow-up after HSCT. Contr…

Human cytomegalovirusCellular immunitymedicine.drug_classvirusesmedicine.medical_treatmentImmunologyCongenital cytomegalovirus infectionHematopoietic stem cell transplantationBiologymedicine.disease_causeVirusChickenpox VaccineCytomegalovirus VaccinesImmunocompromised HostChickenpoxDrug DiscoverymedicineHumansPharmacologyHematopoietic Stem Cell TransplantationVaricella zoster virusvirus diseasesbiochemical phenomena metabolism and nutritionmedicine.diseaseVirologyTransplantationCytomegalovirus InfectionsImmunologyMolecular MedicineAntiviral drugExpert Review of Vaccines
researchProduct

Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles.

2002

Abstract Background: Pre- and perinatal human cytomegalovirus (HCMV) infection remains one of the major causes of mental defects and sensineural hearing loss in children. In addition, it is a prominent infectious complication in immunosuppressed individuals such as AIDS patients or transplant recipients. Therefore, the development of an HCMV vaccine has been given top priority by health care institutions. Study design: Defective subviral particles of HCMV, termed Dense Bodies (DB) contain the dominant target antigens for humoral and cellular immune responses elicited during natural infection. These enveloped particles are released from infected culture cells and can be purified by gradient …

Human cytomegalovirusCytotoxicity ImmunologicImmunogenCytomegalovirusMice TransgenicBiologyAntibodies ViralVirusCell LineCytomegalovirus VaccinesMiceImmune systemAntigenNeutralization TestsVirologymedicineCytotoxic T cellAnimalsHumansMice Inbred BALB CVirionmedicine.diseaseVirologyCTL*Infectious DiseasesImmunizationVaccines InactivatedImmunologyCytomegalovirus InfectionsT-Lymphocytes CytotoxicJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
researchProduct

Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies

2004

International audience; DNA vaccination using a plasmid encoding the rotavirus inner capsid VP6 has been explored in the mouse model of rotavirus infection. BALB/c mice were immunized with a VP6 DNA vaccine by the intramuscular, nasal and oral routes. VP6 DNA vaccination by the nasal and oral routes induced the production of anti-VP6 IgA antibodies by intestinal lymphoid cells. Intramuscular DNA injection stimulated the production of serum anti-VP6 IgG but not serum anti-VP6 IgA antibodies. Protection against shedding of rotaviruses in stools after oral challenge with the murine EDIM rotavirus strain was investigated in the immunized mice. A significant reduction in the level of rotavirus a…

Immunoglobulin A[SDV]Life Sciences [q-bio]virusesAdministration OralAntibodies Viralmedicine.disease_causeImmunoglobulin GFecesMice0302 clinical medicineRotavirusVaccines DNAAntigens ViralMice Inbred BALB CVaccines Synthetic0303 health sciencesvirus diseasesVirus Shedding3. Good healthInfectious DiseasesMolecular MedicineFemaleDNA vaccineEnzyme-Linked Immunosorbent AssayBiologyInjections IntramuscularRotavirus InfectionsDNA vaccination03 medical and health sciencesAntigenmedicineAnimalsViral sheddingAdministration Intranasal030304 developmental biologyGeneral VeterinaryGeneral Immunology and Microbiologyintestinal IgA antibodyRotavirus VaccinesPublic Health Environmental and Occupational HealthVirologyImmunoglobulin ADisease Models AnimalrotavirusImmunizationImmunoglobulin GImmunologybiology.proteinCapsid ProteinsNasal administration030215 immunologyVaccine
researchProduct

Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine).

2009

Combination vaccines that include multiple antigens within one formulation are now widely accepted as an effective means of eliciting protection against several diseases at the same time. Owing to improvements in quality and convenient modes of administration, they have become part of routine pediatric practice. Hexavalent vaccines, including diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b antigens represent the latest advance in the development of combination vaccines. Over 8 years since its first licensure, this review looks at the immunogenicity, efficacy and safety profile of the only hexavalent pediatric vaccine currently in use--Infanrix hexa (diph…

ImmunologyPostmarketing surveillancemedicine.disease_causeDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccineDrug DiscoverymedicineProduct Surveillance PostmarketingHumansVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesHaemophilus VaccinesPharmacologyClinical Trials as TopicTetanusbusiness.industryDiphtheriaPoliovirusmedicine.diseaseVirologyPoliomyelitisVaccinationPoliovirus Vaccine InactivatedImmunologyMolecular Medicinebusinessmedicine.drugExpert review of vaccines
researchProduct

Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review

2022

INTRODUCTION: Rotavirus is one of the most common pathogens causing diarrhea in children <5 years and has a major impact on childhood morbidity and mortality. Since the implementation of rotavirus vaccines into childhood immunization programs across Europe, there has been a reduction in rotavirus burden, including hospitalizations, outpatient cases, costs, and deaths. AREAS COVERED: A systematic literature review identified publications describing the clinical and economic impact of rotavirus vaccinations across Europe, from their introduction in 2006 to the end of 2020. A total of 3,137 articles were identified, of which 46 were included in the review. Included articles reported the impact…

ImmunologydiarrheaRotavirus InfectionsDrug DiscoveryHumansChildren; diarrhea; gastroenteritis; rotavirus; systematic literature review; vaccinesChildChildrenAgedPharmacologySettore MED/38 - Pediatria Generale e Specialisticarotaviruvaccines.Immunization ProgramsVaccinationRotavirus Vaccinessystematic literature reviewInfantvaccinesHospitalizationrotavirusMolecular MedicinegastroenteritiDelivery of Health Caregastroenteritis
researchProduct

Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review

2019

Background Vaccine adjuvants are compounds that significantly enhance/prolong the immune response to a co-administered antigen. The limitations of the use of aluminium salts that are unable to elicite cell responses against intracellular pathogens such as those causing malaria, tuberculosis, or AIDS, have driven the development of new alternative adjuvants such as QS-21, a triterpene saponin purified from Quillaja saponaria. Purpose The aim of this review is to attempt to clarify the mechanism of action of QS-21 through either receptors or signaling pathways in vitro and in vivo with special emphasis on the co-administration with other immunostimulants in new adjuvant formulations, called a…

InflammasomesT-Lymphocytesmedicine.medical_treatmentHerpes zosterPharmaceutical ScienceMonophosphoryl Lipid AAPCs antigen presenting cellsMiceCMI cell mediated immunity0302 clinical medicineDrug DiscoveryHerpes Zoster VaccineMedicineNSCLC non small cell lung carcinomaCancerImmunity CellularVaccines Synthetic0303 health sciencesImmunogenicityIl-2 interleukine 2HIV human immunodeficiency virusLipid A030220 oncology & carcinogenesisCytokinesMolecular MedicineDCs dendritic cellsNK natural killerAdjuvantTLR Toll-like receptorHerpes Zoster VaccineCD cluster of differentiationAntigen-Presenting CellsCTL cytotoxic T lymphocytesHZ herpes zosterMPL 3-deacylated monophosphoryl lipidVaccine adjuvantImmunoadjuvantArticleVZV varicella zoster virus03 medical and health sciencesImmune systemAdjuvants ImmunologicAntigenPAMPs pathogen-associated molecular patternsMalaria VaccinesPRRs pathogen recognition receptorsQS-21 Quillaja saponaria Molina-fraction 21AnimalsMHC major histocompatibility complexMtb Mycobacterium tuberculosis bacteriaSARS severe acute respiratory syndromeAntigen-presenting cellIFN-γ interferon-gamma030304 developmental biologyPharmacologybusiness.industryA-β amyloid-betaTNF-α tumor necrosis factor-alphaSaponinsQS-21MalariaQuillaja saponariaComplementary and alternative medicineTCR T-cell receptorLiposomesImmunologyKLH keyhole limpet hemocyaninbusinessdLN draining lymph nodesMAPK mitogen activated protein kinasePhytomedicine
researchProduct